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Noroviruses (NVs) cause the majority of cases of epidemic nonbacterial gastroenteritis worldwide and contribute to endemic
enteric disease. However, the molecular mechanisms responsible for immune control of their replication are not completely un-
derstood. Here we report that the transcription factor interferon regulatory factor 1 (IRF-1) is required for control of murine NV
(MNV) replication and pathogenesis in vivo. This led us to studies documenting a cell-autonomous role for IRF-1 in gamma in-
terferon (IFN-)-mediated inhibition of MNV replication in primary macrophages. This role of IRF-1 in the inhibition of MNV
replication by IFN- is independent of IFN- signaling. While the signal transducer and activator of transcription STAT-1 was
also required for IFN--mediated inhibition of MNV replication in vitro, class II transactivator (CIITA), interferon regulatory
factor 3 (IRF-3), and interferon regulatory factor 7 (IRF-7) were not required. We therefore hypothesized that there must be a
subset of IFN-stimulated genes (ISGs) regulated by IFN- in a manner dependent only on STAT-1 and IRF-1. Analysis of tran-
scriptional profiles of macrophages lacking various transcription factors confirmed this hypothesis. These studies identify a key
role for IRF-1 in IFN--dependent control of norovirus infection in mice andmacrophages.
Noroviruses (NVs) are a genus of positive-sense RNA virusesthat are the major etiologic agent of epidemic nonbacterial
gastroenteritis worldwide (11, 12). Symptoms of human norovi-
rus infection are generally self-limiting and typically resolve
within 72 h (12), which is consistent with a role for innate antiviral
mechanisms such as interferons (IFNs) in control of symptoms
and replication. Both type I (IFN-) and II (IFN-) IFNs de-
crease viral RNA and protein expression from a human norovirus
replicon (6, 7).Murine noroviruses (MNVs) are culturable viruses
that share structural, biochemical, and genetic features with hu-
man noroviruses and provide a tractable small-animal model for
investigation of NV immunity, pathogenesis, and IFN-mediated
control of NV replication (4, 8, 17, 41, 42).
MNVs replicate in myeloid cells in culture and in vivo (40, 41).
Both IFN- and IFN- play key roles in control of MNV infec-
tion in vivo, since mice deleted of both the IFN- receptor (IFN-
R/) and the IFN- receptor (IFN-R/) aremore suscep-
tible to lethal infection than mice deleted of either IFN receptor
individually (15, 17). Pretreatment with either IFN- or IFN-
limits MNV replication in cultured macrophages and dendritic
cells (8, 15). These studies show, together with studies of human
norovirus replicons (6, 7), that IFNs exert direct antiviral effects
that inhibit NV replication in permissive cells. Furthermore,
IFN- exerts autocrine control of MNV replication in primary
cell cultures, asMNV replicates to a higher titer in cells lacking the
IFN-R than in control cells (41).
IFNs exert direct antiviral effects via induction of the transcrip-
tion of multiple potentially antiviral genes (IFN-stimulated genes
[ISGs]). After binding to their respective receptors, IFN- and
IFN- induce cellular transcription via Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) signaling path-
ways (1, 25, 33). STAT-1 is an essential component of both the
IFN- and IFN- signaling pathways, and a key role for STAT-1
in control of MNV replication is well established. STAT-1-defi-
cient mice (STAT-1/), like mice lacking both the IFN-R and
the IFN-R (IFN-R/), succumb to MNV infection and
have elevated viral titers in multiple tissues (17, 27). Moreover,
similar to cells lacking the IFN-R, cells lacking STAT-1 repli-
cate MNV to a higher level than wild-type (WT) cells (41). In
addition to STAT-1, the autophagy proteins Atg5, Atg16, and
Atg7, but not the degradative function of autophagy, are required
for IFN--dependent control ofMNV replication inmacrophages
(15). However, factors other than STAT-1 and specific autophagy
proteins that are involved in IFN-mediated control of MNV rep-
lication are less well defined.
Interferon regulatory factor 1 (IRF-1) is induced by IFNs via
STAT-1 signaling (1). IRF-1 is a transcription factor that has a role
in the stimulation of cytokines, chemokines, and some ISGs in
response to IFN- (18–20). Importantly, IRF-1 is capable of acti-
vating antiviral programs against a diverse range of RNA viruses
(16, 29, 31) and is required for IFN--mediated inhibition of en-
cephalomyocarditis virus (EMCV) and West Nile virus (WNV)
replication in cultured cells (2, 18). In addition, IRF-1 has been
implicated in IFN--mediated direct antiviral effects against
EMCV (18) and is important for IFN- production in response
to poly(I)-poly(C) in vitro but not in response to Newcastle dis-
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ease virus (24), WNV (2), or poly(I)-poly(C) (30) in vivo. IRF-1
plays additional roles in innate and adaptive immunity. IRF-1-
deficient (IRF-1/) mice exhibit defects in CD8 T cell and natu-
ral killer (NK) cells (24, 28) and exhibit increased TH2 skewing
and decreased production of IFN- by CD4 T cells as a result of
dysregulation of interleukin-12 (22). Thus, the in vivo role of
IRF-1 during a given viral infection could reflect a combination
of direct effects on viral replication in permissive cells and effects
on the cellular innate and adaptive immune responses to infec-
tion.
Here we demonstrate that IRF-1 has important in vivo effects
on MNV replication and pathogenesis that are independent of
effects of IFN- and are consistent with a direct antiviral role for
IRF-1 in IFN--mediated inhibition of MNV replication in pri-
mary macrophages. Studies in cultured macrophages confirm a
key cell-autonomous role for IRF-1 in IFN--mediated inhibition
of MNV replication, and this role does not require autocrine se-
cretion of IFN-. Importantly, the role for IRF-1 is highly spe-
cific, since IFN- does not require other signaling pathways, in-
cluding those dependent on class II transactivator (CIITA),
interferon regulatory factor 3 (IRF-3), or interferon regulatory
factor 7 (IRF-7), to elicit an antiviral state for MNV. Confirming
this specificity, IFN- induces changes in the expression of many
genes, but only a subset of these depends on both STAT-1 and
IRF-1 signaling.
MATERIALS AND METHODS
Virus stocks and plaque assay. Plaque-purified MNV-1.CW3 was used
for all experiments (38). Concentrated virus stocks were prepared by in-
fecting RAW 264.7 cells (ATCC, Manassas, VA) (4). Viral titers were
determined by a previously described plaque assay (41), with the follow-
ing modifications. Suspension-adapted RAW 264.7 cells were plated at a
density of 2  106 cells per well in 6-well plates and allowed to adhere
overnight at 37°C and 5% CO2. Cells were inoculated for 1 h at room
temperature on a rocker, after which the inoculumwas removed and cells
were overlaid with 2 ml/well of Eagle minimum essential medium (Medi-
atech, Manassas, VA) containing 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 100 g/ml penicillin, 100 g/ml streptomycin, 10 mM
HEPES, and 1% methylcellulose (viscosity, 1,500 centipoise; Sigma, St.
Louis, MO). After 2 to 4 days of incubation at 37°C and 5% CO2, the
overlay was removed and plaques were visualized with 1% crystal violet in
20% ethanol.
Mice, inoculations, and tissue preparation. Mice were bred and
housed under specific-pathogen-free conditions in accordance with fed-
eral and university regulations (3). All mice used were either derived from
C57/BL6 embryonic stem (ES) cells or extensively backcrossed to C57/
BL6 mice. IRF-1/ and CIITA-deficient (CIITA/) mice were pur-
chased from The Jackson Laboratory, Bar Harbor, ME. IFN-R/ and
IFN-R/ (17, 26) mice were originally obtained from Michel Aguet
(Swiss Institute for Experimental Cancer Research, Lausanne, Switzer-
land). IRF-3 and IRF-7 doubly deficient (IRF37/) mice (10) were a
generous gift fromMichael Diamond (Washington University, St. Louis,
MO). Seven- to 9-week-oldmice were orally inoculated with 3 105 PFU
of MNV-1.CW3 (38). Five days after inoculation, tissues were harvested
into 2-ml sterile, screw-top tubes containing 250 l of 1-mm zirconia-
silica beads (BioSpec Products, Bartlesville, OK) and stored at 80°C.
Tissues were homogenized in 1 ml of complete Dulbecco modified Eagle
medium (DMEM) by use of a MagNA Lyser machine (Roche Applied
Science, Hague Road, IN), and virus titers were determined by plaque
assay. For lethality and in vivo titer experiments involving blocking of
IFN- signaling, 2.5 mg of purified endotoxin-free IFNAR-1-blocking
antibody (MAR1-5A3) (32) or isotype-matched MOPC-21 antibody
(BioXcell, West Lebanon, NH) was administered intraperitoneally 1 day
prior to infection. For lethality experiments, a second dose of 0.5 mg was
administered intraperitoneally 4 days after infection.
Cells, infections, and IFN treatment. Primary bone marrow-derived
macrophages were prepared as described previously (15). Briefly, bone
marrow (43) was incubated in culture medium (DMEM supplemented
with 10% FBS, 5% defined equine serum, 10% CMG14-12 supernatant
[37], 1%MEM nonessential amino acids, 1 mM sodium pyruvate, 2 mM
L-glutamine) for 7 days, after which adherent cells were harvested and
replated on fresh culturemedium. For in vitro infections, cells were plated
at a density of 1 105 cells/well in 24-well dishes or 1 106 cells/well in
6-well dishes. Infections were performed at day 10 of in vitro culture after
12 to 16 h of treatment with recombinant IFN- or IFN- (R&D Systems,
Minneapolis,MN) at the indicated doses (15, 41). After 30min of absorp-
tion at 4°C, cells were washed and IFNs added back into treated cultures.
Cells were harvested by freezing at80°C.
Microarray assay and meta-analysis of differentially expressed
genes. To identify genes that are regulated by IFN- in a STAT-1- and
IRF-1-dependent manner, RNAs collected from IFN--treated and un-
treated C57BL/6 (WT), IRF-1/, STAT-1/, IRF37/, and
CIITA/ bone marrow-derived macrophages were profiled using
AffymetrixMouse 1.0Gene ST arrays. Briefly, bonemarrow-derivedmac-
rophageswere prepared as described above. After 7 days of in vitro culture,
adherent cells were harvested and replated at a density of 5 106 cells/well
in 10-cm dishes. RNA was collected at day 10 of in vitro culture after 12 h
of treatment with 10 U/ml of recombinant IFN-. The microarray assays
were performed in three independent experiments. Microarray data were
normalized using the robust multiarray average normalization routine in
Affymetrix’s Expression Console software. Differential expression analy-
sis was carried out in Matlab. Three different comparison schemes were
TABLE 1 Primers used in this study
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employed. First, the gene expression profile of untreated WT bone mar-
row-derivedmacrophages was compared to the profiles of untreated IRF-
1/, STAT-1/, IRF37/, and CIITA/ bone marrow-derived
macrophages. Second, the gene expression profile of IFN- treated WT
bone marrow-derived macrophages was directly contrasted with that of
untreated WT bone marrow-derived macrophages. Lastly, the gene ex-
pression profiles of the various IFN--treatedmacrophages were normal-
ized to the respective control profiles from untreated macrophages and
then evaluated for significant differences in fold change compared to the
similarly normalized profile of IFN--treated WTmacrophages. The sta-
tistical significance of the difference in mean expression levels for each
gene was assessed by performing a standard two-tailed, two-sample un-
paired t test, assuming unknown and unequal variances between the sam-
ples. Genes were also independently ranked based on their significance in
separating two labeled groups, which was assessed by computing the area
between the empirical receiver operating characteristic (ROC) curve and
a random binary classifier slope. Gene expression differences were con-
sidered significant if the t test-based nominal P value was0.05 and the
area between the ROC curves was 0.25. Differentially expressed genes
were evaluated for pathway enrichment by gene set overlap analysis using
mSigDB (34a).
Validation of microarray analyses. To validate our microarray find-
ings, a subset of genes was selected for analysis by quantitative reverse
transcription-PCR (qRT-PCR) (primer sequences are given in Table 1).
Total RNAs were isolated from IFN--treated and untreated C57BL/6,
IRF-1/, STAT-1/, IRF37/, and CIITA/ bone marrow-de-
rived macrophages, and cDNAs were synthesized (13, 14). qRT-PCR was
performed with SYBR green (Invitrogen, Carlsbad, CA). Viral transcript
levels were normalized to the level of transcription of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)within each sample, using the		CT
method (where CT is the threshold cycle) (21).
Statistical analysis.All data other thanmicroarray data were analyzed
using GraphPad Prism software (GraphPad Software, San Diego, CA).
For in vitro experiments, statistical analyses were performed by one-way
analysis of variance (ANOVA) (with Tukey’s posttest), unless specifically
stated otherwise. In vivo viral titer data were analyzed with the nonpara-
metric Mann-Whitney test. Survival curves were analyzed using the log
rank test. All differences not specifically stated to be significant were in-
significant (P 0.05).
RESULTS
IRF-1 restricts MNV replication in vivo. Previous studies dem-
onstrated that MNV is controlled in vivo by a combination of
redundant and unique IFN--dependent and IFN--dependent
mechanisms (15, 17). IFN--mediated antiviral effects are re-
vealed and can be studied when IFN- signaling is inhibited (15,
17).To assess the possible contribution of IRF-1 to both IFN--
and IFN--dependent control ofMNV in vivo, we compared viral
titers in IRF-1/, IFN-R/, and C57BL/6 (WT) control mice
treated with either a monoclonal antibody (MAb) against the
IFNAR-1 subunit of the IFN-R (anti-IFNAR) (32) or an iso-
type control MAb prior to oral (p.o.) inoculation with MNV. It
has been shown previously that MNV replication is restricted to
the intestine, spleen, and mesenteric lymph nodes (MLN) in WT
mice but is disseminated and present at increased levels in mice
with various immune deficiencies, including deficiencies in IFN
FIG 1 IRF-1 and the IFN-R restrict MNV replication in mice with compromised IFN- signaling. WT, IRF1/, and IFN-R/mice were treated with a
control or anti-IFNAR MAb before inoculation with 3 105 PFU of MNV. Viral titers were determined in the distal ileum (A), mesenteric lymph nodes (B),
spleen (C), liver (D), lung (E), and brain (F). Seven to 10 mice were used per group, and data represent at least three independent experiments. Statistically
significant differences in the anti-IFNAR-treated IRF1/ and IFN-R/ mice relative to WT mice are indicated by asterisks (**, P  0.01; ***, P  0.001).
Other significant differences are discussed in the text. The limit of detection is indicated by a dashed line. Bars indicate arithmetic means.
Control of MNV by IFN- Requires IRF-1
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signaling (17). IRF-1/mice treated with control MAb had sig-
nificantly increased viral titers in the intestine (P  0.05), spleen
(P 0.01),MLN (P 0.01), liver (P 0.01), and lung (P 0.05)
compared to WT and IFN-R/mice treated with control MAb
(Fig. 1A to F) at day 5 postinoculation. Furthermore, untreated
IRF-1/mice had significantly increased virus titers (P 0.001)
in the intestine, spleen, MLN, and liver compared to WT and
IFN-R/mice at day 3 postinoculation (data not shown). Ad-
ditionally,WTmice treatedwith the anti-IFNARMAbhad detect-
able levels of MNV in the brain, lung, and liver, in addition to
increased replication in the distal ileum, spleen, andMLN (Fig. 1A
to F). Notably, however, deficiency of either IRF-1 or the IFN-R
resulted in significant enhancement of viral replication in all or-
gans compared to treatment of WT mice with the anti-IFNAR
MAb (Fig. 1A to F). Together, these data demonstrate that IRF-1 is
important for restriction of MNV replication in vivo. Further-
more, when compensatory IFN- signaling is inhibited by ad-
ministration of blocking MAb to reveal potential IFN- effects,
both IRF-1 and the IFN-R are critical for control of MNV repli-
cation.
IRF-1 is critical for protection against lethal MNV infection
when IFN- signaling is inhibited. In addition to elevated viral
titers, mice deficient in IFN signaling (STAT-1/ and IFN-
R/mice) succumb to MNV infection (17, 27). To evaluate
whether IRF-1 deficiency also results in increased susceptibility to
lethal MNV infection, we monitored the survival of MNV-in-
fected WT, IRF-1/, and IFN-R/mice that had been treated
with control or anti-IFNAR MAb. None of the mice treated with
control MAb succumbed to MNV infection (Fig. 2). Unlike IFN-
R/ mice (17), anti-IFNAR-treated IFN-R/ mice did
not display significantly increased lethality after MNV infection
(Fig. 2). Together with the data in Fig. 1 indicating significant
effects of anti-IFNAR antibody treatment on MNV pathogenesis,
these data indicate that treatment with this antibody only partially
blocks the in vivo effects of type 1 IFNs. Nevertheless, IRF-1/
mice treated with anti-IFNARMAb displayed significant lethality
after MNV infection compared to control MAb-treated IRF-1/
mice and control MAb or anti-IFNAR MAb-treated WT or IFN-
R/mice (Fig. 2). Therefore, when IFN- signaling is inhib-
ited, there is an essential requirement for IRF-1 for survival after
MNV infection.
While IRF-1 plays a role in multiple aspects of viral immunity
(18–20, 22, 24, 28), our observations in vivo that IRF-1 is impor-
tant for control of MNV both with and without inhibition of
IFN- signaling raise the possibility that IRF-1 is important for
IFN-- aswell as IFN--mediated control ofMNVreplication in
permissive cells.
IRF-1 is required for IFN-- but not IFN--mediated inhi-
bition of MNV replication in primary macrophages. Based on
these results and the tropism ofMNV for macrophages (41), we
hypothesized that IRF-1 would be required for IFN-mediated
control of MNV in macrophages. To address this hypothesis,
we generated bone marrow-derived macrophages from WT
and IRF-1/ mice and inoculated them with MNV at a high
(5) or low (0.05) multiplicity of infection (MOI). There was no
statistically significant difference in MNV replication in un-
treated WT and IRF-1/macrophages over 36 h (Fig. 3A and
B). However, while treatment of WT macrophages with IFN-
significantly inhibited MNV replication, in a dose-dependent
manner (P  0.05 for 100 and 10 U/ml IFN- at an MOI of 5
and for 100, 10, and 1 U/ml IFN- at anMOI of 0.05), there was
a significant defect in IFN--mediated inhibition of MNV rep-
lication in IRF-1/macrophages (Fig. 4A and B). In contrast,
treatment with IFN- inhibited MNV comparably in IRF-1/
and WT macrophages (Fig. 4C and D). Thus, IRF-1 is required
for IFN- to control MNV in macrophages but is dispensable
for its control by IFN-.
Inhibition of MNV replication occurs in IFN--activated
macrophages independent of the IFN- receptor. According
FIG 2 IRF-1 is critical for resistance to lethal infection with MNV when
IFN-ɑ signaling is inhibited. WT, IRF1/, and IFN-R/ mice were
treated with a control or anti-IFNAR MAb, inoculated with 3  105 PFU of
MNV, andmonitored for survival for 21 days. Sevenmicewere used per group,
and data represent at least three independent experiments. Survival differences
between anti-IFNARMAb-treatedWT and IRF-1/mice were significant (P

 0.0003).
FIG 3 Replication of MNV in WT and IRF-1/ macrophages is similar.
Macrophages were inoculated withMNV at anMOI of 5 (A) or 0.05 (B). Viral
titers shown represent data from three independent experiments and are
means  standard errors of the means (SEM). No significant differences be-
tween the growth curves were detected by the unpaired t test.
Maloney et al.
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to some reports, the antiviral effect of IFN- can require the IFN-
R (36), and IRF-1 is important for production of IFN- in
response to certain stimuli (24). Therefore, we examined the po-
tential involvement of autocrine production of IFN- in IFN--
induced, IRF-1-dependent inhibition ofMNV replication inmac-
rophages. Macrophages were generated from IFN-R/ mice
and treated with increasing doses of IFN- or medium alone be-
fore inoculationwithMNVat high and lowMOIs. As observed for
WT macrophages (Fig. 4), treatment of IFN-R/ macro-
phages with IFN- resulted in significant inhibition of MNV rep-
lication (Fig. 5A and B), in a dose-dependent manner (P  0.05
for 100 and 10 U/ml IFN- at an MOI of 5 and for 100, 10 and 1
U/ml IFN- at an MOI of 0.05). The effects of IFN- were com-
parable between WT and IFN-R/ macrophages. These data
demonstrate that the IFN-R is not required for IFN--medi-
ated inhibition of MNV replication in macrophages. This is con-
sistent with our finding in vivo that IFN- and IRF-1 have func-
tions independent of the effects of IFN-ɑ (Fig. 1).
IFN--mediated control of MNV replication requires
STAT-1butnot IRF-3, IRF-7, orCIITA.The transcription factors
STAT-1, IRF-1, and CIITA are important for induction of specific
ISGs (1) in response to IFN-. To investigate the involvement of
other IFN--related signaling molecules in IFN--mediated con-
trol of MNV replication, we generated macrophages from STAT-
1/ and CIITA/ mice and evaluated their ability to control
MNV replication after treatment with IFN-. As controls, we also
analyzed IFN--mediated control of MNV in macrophages gen-
erated from mice deficient in the IRF-1-related transcription fac-
tors IRF-3 and IRF-7 (IRF37/mice). Treatment of CIITA/
FIG 4 IRF-1 is required for IFN--mediated control ofMNV replication in primarymacrophages.WT and IRF-1/macrophages were treated with increasing
doses of IFN- (A and B), IFN- (C and D), or medium alone, inoculated with MNV at an MOI of 5 (A and C) or 0.05 (B and C), and harvested at 12 or 24 h
postinfection, respectively. Data were collected from three to eight independent experiments and are presented as mean titers  SEM. Asterisks indicate
significant differences in viral titer between WT and IRF-1/ cells (**, P 0.01; ***, P 0.001). No significant differences were determined between titers in
WT and IRF-1/ cells for any dose of IFN- used.
FIG 5 Inhibition of MNV replication in IFN--activated macrophages is
STAT-1 dependent but IFN-R,CIITA, IRF-3, and IRF-7 independent. IFN-
R/, CIITA/, IRF37/, and STAT-1/ macrophages were treated
with increasing doses of IFN- ormedium alone before inoculation at anMOI
of 5 (A) or 0.05 (B). These experiments were conducted concurrently with the
experiments for Fig. 4; therefore, the data forWTmacrophages are repeated in
the figure for comparison. Data were collected from at least three independent
experiments. Asterisks indicate significant differences in viral titers relative to
those in WT cells (*, P 0.05; **, P 0.01; ***, P 0.001).
Control of MNV by IFN- Requires IRF-1





ber 10, 2014 by W






and IRF37/ macrophages with IFN- significantly inhibited
MNV replication, in a dose-dependent manner, at both high and
low MOIs (Fig. 5A and B). However, STAT1/ macrophages
were unable to control MNV replication even after stimulation
with 100 U/ml of IFN-. These data demonstrate that the signal-
ingmolecules IRF-1 and STAT-1, but not CIITA, IRF-3, or IRF-7,
are required for IFN--mediated inhibition of MNV replication
in macrophages.
Identification of STAT-1- and IRF-1-dependent subset of
IFN--regulated genes. Based on the above observations, we hy-
pothesized that there would be a subset of IFN--regulated genes
that depend on STAT-1 and IRF-1 but not on IRF-3, IRF-7, or
CIITA for their expression. To address this hypothesis, we per-
formed microarray analyses comparing steady-state transcript
levels of 28,853 mouse gene transcripts in WT, IRF-1/, STAT-
1/, CIITA/, and IRF37/macrophages after 12 h of treat-
ment with IFN-, using three independent biological replicates.
The 12-h time point was selected because this is sufficient to in-
duce an antiviral state that limits MNV replication (Fig. 4 and 5).
We identified 359 geneswhose expressionwas changed2-fold in
WTmacrophages by IFN- treatment (216 were upregulated and
143 were downregulated). We then determined which of these
genes depend on both STAT-1 and IRF-1 but not on CIITA or
IRF-3/7 for regulation by IFN-. We found that 38 genes were
differentially regulated by IFN- when either CIITA or IRF-3/
IRF-7 was missing. We focused on the remaining CIITA- and
IRF-3/IRF-7-independent genes (Table 2; Fig. 6). Ninety-seven
genes required STAT-1 but not IRF-1 for upregulation by IFN-
(group A) (Table 2; Fig. 6). One hundred genes were downregu-
lated in a manner dependent on STAT-1 but not IRF-1 (group B)
(Table 2; Fig. 6). Consistent with our hypothesis, a set of genes did
depend on both STAT-1 and IRF-1 (groups C and D) (Table 2;
Fig. 6) for their regulation by IFN-. Ten genes required just IRF-1
for downregulation by IFN-. Eighteen genes did not meet statis-
tical criteria for assignment to any of the designated groups in
Table 2.
Validation of microarray analysis by qRT-PCR. To assess
whether the gene expression changes we detected by microarray
analysis could be verified by an independent methodology, we
selected 11 genes with various patterns of transcription factor de-
pendence and measured their transcript levels by qRT-PCR. To
this end, we isolated RNAs from untreated and IFN--treated
WT, IRF-1/, IRF37/, STAT-1/, and CIITA/ macro-
phages for analysis (Fig. 7). When we compared the fold changes
in expression induced by IFN- in the various gene-deficientmac-
rophages to those observed inWTmacrophages, we found that for
82% (9 of 11 genes) of the genes, our microarray analyses accu-
rately predicted the gene’s dependence on the various transcrip-
tion factors for responsiveness to IFN- (Fig. 7). These data sup-
port the bioinformatic analysis of microarray data indicating
patterns of transcription factor dependence for IFN--regulated
genes.
Pathway analysis of gene sets identified by microarray anal-
ysis. To identify the gene pathways that these STAT-1- and IRF-
1-dependent genes contribute to in IFN--activated macro-
phages, we analyzed groups A toD (Table 2) separately by gene set
overlap analysis using mSigDB. We found enrichment for several
metabolic pathways, such as pyrimidinemetabolism, arginine and
proline metabolism, and nicotinate and nicotinamide metabo-
lism, among genes that were regulated by IFN- in a manner de-
pendent on STAT-1 but not on IRF-1, IRF-3, IRF-7, or CIITA
(Fig. 8). Conversely, we found enrichment of several immune
response pathways in genes that were inhibited by STAT-1 (Fig.
8). These included genes involved in the Toll-like receptor
(TLR) signaling pathway, the IL-7 pathway, the NFAT path-
way, and glutathionemetabolism. The genes that required both
STAT-1 and IRF-1 for upregulation in response to IFN- were
enriched for stress-activated protein kinase signaling, JNK cas-
cade, and interleukin/cytokine binding pathways, while the
genes that were inhibited by IFN- in a manner dependent on
both STAT-1 and IRF-1 were enriched for lipid metabolism,
steroid metabolism, cholesterol biosynthesis, and terpenoid
biosynthesis.
DISCUSSION
IFNs are likely vital to the host defense against human norovi-
ruses and are important for inhibition of MNV (8, 15, 17, 41).
However, the antiviral mechanisms that IFNs induce to combat
NVs and the transcription factors involved in these responses
are not well defined. In this report, we demonstrate a critical
role for the transcription factor IRF-1 in control of MNV rep-
lication in vivo. Furthermore, we show that in the absence of
IFN- signaling, IRF-1 is essential for survival after MNV
infection. We also demonstrate that IRF-1 is required for the
control of MNV by IFN- in primary macrophages. Despite
previous studies that suggest a role for IRF-1 in IFN--in-
duced antiviral responses, we found that IRF-1 is dispensable
for control of MNV by IFN- in cultured macrophages. Fi-
nally, we demonstrated an additional requirement for STAT-1,
but not autocrine IFN-, CIITA, IRF-3, or IRF-7, in IFN--
induced control of MNV in macrophages. Consistent with the
importance of STAT-1 and IRF-1 in the antiviral effects of
TABLE 2 Transcription factor requirements of genes that were responsive to IFN- in macrophagesa
Parameter
Requirement or value for gene category
Group A Group B Group C Group D Group E Group F
Change in gene expression after
treatment with IFN-
Requires STAT-1 for change      
Requires IRF-1 for change      
Requires IRF-3/IRF-7 for change      
Requires CIITA for change      
No. of genes in category 97 100 49 26 21 0
a Genes whose expression profiles were changed by IFN- were identified and grouped based on the requirement of STAT-1, IRF-1, CIITA, IRF-3, or IRF-7 for this change.
Maloney et al.





ber 10, 2014 by W






FIG 6 Heatmaps of the genes assigned to groupA (A), groupB (B), groupC (C), and groupD (D) bymicroarray analyses (see Table 2). GroupA represents genes that
are upregulated by IFN- in a STAT-1-dependent manner, group B represents genes that are downregulated by IFN- in a STAT-1-dependent manner, group C
representsgenes thatareupregulatedbyIFN- inanIRF-1-andSTAT-1-dependentmanner, andgroupDrepresentsgenes thataredownregulatedbyIFN- inanIRF-1-
and STAT-1-dependent manner. The heat maps represent row-normalized Z-score values per gene. Expression values of1 standard deviation above the expression
level in untreatedWTmacrophages are indicated in red, and values of1 standard deviation below theWT expression level are indicated in blue.
Control of MNV by IFN- Requires IRF-1





ber 10, 2014 by W






IFN-, we used microarrays and bioinformatics to show that
there is a defined subset of genes whose regulation by IFN-
requires these two transcription factors.
IRF-1 in IFN--mediated responses in vivo. Previous studies
with IRF-1/mice have confirmed the importance of IRF-1 for
defense against both EMCV and WNV in vivo (2, 18). However,
due to the complex nature of IRF-1 actions in host defense, the in
vivo contribution of IRF-1 as a direct effector of IFN- signaling in
infected cells is unclear. For example, studies of immune re-
sponses toWNV found that IRF-1 is required for IFN--mediated
control of viral replication in macrophages and for shaping the
antigen-specific CD8 T cell response (2). Furthermore, since
IRF-1 contributes to both IFN- and IFN- responses to EMCV
infection in vitro, it is difficult to ascertain the specific contribu-
tion of IRF-1 to IFN--dependent responses in vivo in this model
(18). Our finding that mice deficient in either IRF-1 or IFN-R
have elevated viral titers when IFN- signaling is blocked is con-
sistent with the idea of shared functions for IRF-1 and IFN- in
vivo and strongly suggests that the antiviral effects of IFN- are
mediated at least in part by IRF-1 in vivo.
IFN--independent functions of IRF-1. Our studies with
blocking antibody (Fig. 1) revealed a role for IRF-1 that is consis-
tent with a role in mediating IFN- responses in vivo. Interest-
ingly, our studies of viral replication in WT, IRF-1/, and IFN-
R/mice and our survival studies have also revealed functions
for IRF-1 in restrictingMNV replication that cannot be explained
by its role in IFN- signaling. IRF-1/mice are highly suscepti-
ble to lethal MNV infection under conditions where IFN-R/
mice are not. Moreover, IRF-1/mice treated with controlMAb
displayed significantly enhanced replication and viral dissemina-
tion of MNV (but not increased lethality) compared to IFN-
R/ and WT mice treated with control MAb (Fig. 1) for every
organ tested except the brain. This enhanced replication, while
not of the same magnitude, paralleled the increased replication
and viral dissemination induced in WT mice treated with anti-
IFNAR and suggests additional functions of IRF-1 inmediating at
least some of the effects of IFN-. However, in primary macro-
phages, we observed that IRF-1 is dispensable for inhibition of
MNV by IFN- (Fig. 4). Furthermore, unlike what is seen for
WNV infection, we did not observe a significant increase in repli-
cation in untreated IRF-1/ macrophages compared to WT
macrophages (Fig. 3) that could explain elevated viral replication
in vivo. Further studies may reveal cell type- and tissue-specific
requirements for IRF-1 in IFN--independent but IFN--de-
pendent control of MNV replication.
STAT-1- and IRF-1-dependent gene pathways. Although
STAT-1 and IRF-1 have well-established activities against a di-
verse range of RNA viruses, few STAT-1- and IRF-1-dependent
individual antiviral effectors have been identified to date. One
such effector is viperin (9), whose activity has been demonstrated
FIG 7 Validation of microarray analyses by qRT-PCR. WT, IRF-1/, CIITA/, IRF37/, and STAT-1/macrophages were treated with 10 U of IFN-
orwithmediumalone. Transcription levels of select geneswere examined after 12 h of treatment.Datawere collected from three independent experiments. Genes
assigned to group A (A), group B (B), group C (C), group D (D), and group E (E) by microarray analyses (see Table 2) were examined. Asterisks indicate
significant differences in transcript levels relative to those in WT cells (*, P 0.05; **, P 0.01; ***, P 0.001).
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against several families of viruses, including orthomyxoviruses
(39), rhabdoviruses (34), and flaviviruses (35). However, viperin
is not required to control MNV replication in primary macro-
phages or in vivo (L. B. Thackray and H. W. Virgin, unpublished
data). Clearly, there is a need to identify STAT-1- and IRF-1-
regulated processes that control MNV replication control. Inter-
estingly, we showed that theAtg5-Atg12/Atg16L1 autophagosome
elongation protein complex, but not the degradative activity of the
autophagy pathway, is required for IFN--mediated inhibition of
MNV replication inmacrophages (15). This property of the Atg5-
Atg12/Atg16L1 complex is shared with IRF-1, as shown here, in
that both are required for the effects of IFN- but not IFN- on
MNV replication in macrophages. Therefore, it is intriguing to
speculate that IRF-1 regulates a key early step in an IFN-/IRF-1/
STAT-1/Atg5-Atg12/Atg16L1-dependent antiviral mechanism.
Our recent work showed that IFN- blocks the formation of the
membranous norovirus replication complex in an Atg5-Atg12/
Atg16L1-dependent manner (15). Interestingly, the microarray
analyses in this study revealed that IFN- downregulates compo-
nents of lipid and cholesterol biogenesis pathways via an IRF-1-
and STAT-1-dependent mechanism. Upregulation of compo-
nents of cholesterol biogenesis pathways occurs in cells stably ex-
pressing a human norovirus replicon or infected with WNV (5,
23). We speculate that changes in cellular lipids mediated by
IFN- alter membrane rearrangements and trafficking, in an au-
tophagy protein-dependent manner, so as to inhibit formation of
the replication complex. Future studies of the IRF-1- and/or
STAT-1-dependent IFN--mediated transcriptional regulation
identified here may uncover novel antiviral mechanisms that can
be harnessed as antimicrobial treatments.
FIG 8 Gene overlap analyses of the genes assigned to group A (A), group B (B), group C (C), and group D (D) by microarray analyses (see Table 2). The x axis
represents the P value, indicating the significance of enrichment for any given gene set. The values are plotted on a negative log10 scale. All gene sets with values
of1.3 on the x axis were significantly enriched.
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